Topotecan (TPT) is a DNA topoisomerase I inhibitor that has shown anti-cancer effects on gastric cancer and the results from its testing suggest that ASCT2 is an anti-cancer target for this compound, as it presented the same effects as ASCT2 knockdown [79]. Here, SLC1A5 is linked to gastric cancer.